Cargando…
ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication
Although podophyllotoxin (POD) demonstrates high efficiency to inhibit various cancers, its clinic application is limited to poor bioavailability. Nanoparticles derived from homodimeric prodrugs with high drug loading potential are emerging as promising nanomedicines. However, complete intracellular...
Autores principales: | Liang, Bingfeng, Zhou, Dangxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583822/ https://www.ncbi.nlm.nih.gov/pubmed/34747277 http://dx.doi.org/10.1080/10717544.2021.1995076 |
Ejemplares similares
-
pH and ROS sequentially responsive podophyllotoxin prodrug micelles with surface charge-switchable and self-amplification drug release for combating multidrug resistance cancer
por: Li, Chao, et al.
Publicado: (2021) -
Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs
por: Fan, Hua-yang, et al.
Publicado: (2021) -
Target-Directed Self-Assembly of Homodimeric Drugs
Against β-Tryptase
por: Giardina, Sarah F., et al.
Publicado: (2018) -
Methyl Jasmonate Regulates Podophyllotoxin Accumulation in Podophyllum hexandrum by Altering the ROS-Responsive Podophyllotoxin Pathway Gene Expression Additionally through the Down Regulation of Few Interfering miRNAs
por: Hazra, Saptarshi, et al.
Publicado: (2017) -
Programmed ROS/CO-releasing nanomedicine for synergetic chemodynamic-gas therapy of cancer
por: Zhao, Bin, et al.
Publicado: (2019)